CA2692775A1 - Procedes d'amelioration de la fonction cognitive en utilisant des composes non peptidiques - Google Patents

Procedes d'amelioration de la fonction cognitive en utilisant des composes non peptidiques Download PDF

Info

Publication number
CA2692775A1
CA2692775A1 CA 2692775 CA2692775A CA2692775A1 CA 2692775 A1 CA2692775 A1 CA 2692775A1 CA 2692775 CA2692775 CA 2692775 CA 2692775 A CA2692775 A CA 2692775A CA 2692775 A1 CA2692775 A1 CA 2692775A1
Authority
CA
Canada
Prior art keywords
compound
formation
addls
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2692775
Other languages
English (en)
Other versions
CA2692775C (fr
Inventor
Grant A. Krafft
Todd Pray
William F. Goure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acumen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692775A1 publication Critical patent/CA2692775A1/fr
Application granted granted Critical
Publication of CA2692775C publication Critical patent/CA2692775C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CA2692775A 2007-07-12 2007-07-12 Procedes d'amelioration de la fonction cognitive en utilisant des composes non peptidiques Expired - Fee Related CA2692775C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/073410 WO2009008891A1 (fr) 2007-07-12 2007-07-12 Procédés d'amélioration de la fonction cognitive en utilisant des composés non peptidiques

Publications (2)

Publication Number Publication Date
CA2692775A1 true CA2692775A1 (fr) 2009-01-15
CA2692775C CA2692775C (fr) 2015-03-24

Family

ID=39272501

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2692775A Expired - Fee Related CA2692775C (fr) 2007-07-12 2007-07-12 Procedes d'amelioration de la fonction cognitive en utilisant des composes non peptidiques

Country Status (5)

Country Link
EP (1) EP2173340B1 (fr)
CA (1) CA2692775C (fr)
ES (1) ES2426501T3 (fr)
MX (1) MX2010000369A (fr)
WO (1) WO2009008891A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (fr) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Procédé pour le traitement des amyloses
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012024187A1 (fr) 2010-08-14 2012-02-23 Abbott Laboratories Protéines de liaison bêta-amyloïdes
US11439623B2 (en) * 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029773A1 (en) * 2004-05-24 2010-02-04 Ludwig-Maximilians-Universitat Munchen Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift)
CA2652449A1 (fr) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Procedes de criblage pour modulateurs de beta-amyloide

Also Published As

Publication number Publication date
MX2010000369A (es) 2010-07-02
ES2426501T3 (es) 2013-10-23
EP2173340B1 (fr) 2013-07-10
EP2173340A1 (fr) 2010-04-14
CA2692775C (fr) 2015-03-24
WO2009008891A1 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
CA2692775C (fr) Procedes d'amelioration de la fonction cognitive en utilisant des composes non peptidiques
US8962677B2 (en) Methods of restoring cognitive ability using non-peptidic compounds
EP2170322B1 (fr) PROCÉDÉS DE MODIFICATION D'OLIGOMÈRES AMYLOÏDES ß AU MOYEN DE COMPOSÉS NON PEPTIDIQUES
US20110098309A1 (en) Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US20230201184A1 (en) Compositions and methods for treating schizophrenia
JP6471100B2 (ja) Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
US20080262047A1 (en) Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
US8609649B2 (en) Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
US20120322879A1 (en) Use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2009009768A2 (fr) Procédés consistant à inhiber la formation de ligands diffusables d'amyloide-b utilisant des composés d'acylhydrazide
US9006283B2 (en) Methods of modifying amyloid β oligomers using non-peptidic compounds
RU2461377C2 (ru) Способ улучшения когнитивной функции (варианты)
RU2448694C2 (ru) Cпособ противодействия образованию нейротоксичных белков addl (варианты), способ модуляции нейрональной дисфункции или нейротоксичности посредством непептидного соединения и композиция (варианты) на его основе
JP2021520412A (ja) タンパク質ミスフォールディング疾患のための療法
JP2008303144A (ja) アミロイド疾患の治療およびモニタリングのための薬剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170712